Investor Presentation Q1 2023

48 Investor presentation First three months of 2023 Insulin icodec, a basal insulin intended for once-weekly treatment, may reduce the disease burden for patients Bringing the strongest value proposition to market Insulin icodec phase 3 programme completed in 2022 Reduction of disease burden with once-weekly treatment ONWARDS 1 984 people insulin-naïve, 78-week, vs insulin glargine U100 ONWARDS 2 526 people on basal, 26-week, vs insulin degludec Tested for superior HbA1c and TiR vs glargine and standard-of-care and similar safety profile of Tresiba® ONWARDS 3 588 people insulin-naïve, 26-week, vs insulin degludec App-based offering and connected smart pen to optimise titration and support compliance and data collection ONWARDS 4 582 people on both basal and bolus, 26-week, vs insulin degludec ONWARDS 5 1,085 people, insulin-naïve using app-based dosing recommendations, 52-week Reduced environmental footprint ONWARDS 6 582 people, type 1 diabetes using bolus insulin, 52-week, vs insulin degludec TIR: Time-in-range Note: For ONWARDS 1 and ONWARDS 6 main phases are completed Novo NordiskⓇ

View entire presentation